

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13751-0055US1	Application No. 10/540,959
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Paul D. Rennert	
		Filing Date April 4, 2006	Group Art Unit 1644

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	1	EP1062949	12/27/2000	EP				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	2	Brams, P. et al., "A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation," International Immunopharmacology Elsevier, Amsterdam, NL (2001), 1(2):277-294.
	3	Saxena, M. et al., "Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTO)," The Journal of Biological Chemistry (1999), 274(17):11693-11700.
	4	Umetsu Dale, T. et al., "Asthma: an epidemic of dysregulated immunity," Nature Immunology (2002, 3(8):715-720.
	5	Xia T., et al., "Cimetidine inhibits production of interferon gamma and tumor necrosis factor alpha by splenocytes in aplastic anemic mice," Acta Pharmacologica Sinica (2001), 22(3):239-242.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	